Your browser doesn't support javascript.
loading
Tetrahydrofuran-Based Transient Receptor Potential Ankyrin 1 (TRPA1) Antagonists: Ligand-Based Discovery, Activity in a Rodent Asthma Model, and Mechanism-of-Action via Cryogenic Electron Microscopy.
Terrett, Jack A; Chen, Huifen; Shore, Daniel G; Villemure, Elisia; Larouche-Gauthier, Robin; Déry, Martin; Beaumier, Francis; Constantineau-Forget, Léa; Grand-Maître, Chantal; Lépissier, Luce; Ciblat, Stéphane; Sturino, Claudio; Chen, Yong; Hu, Baihua; Lu, Aijun; Wang, Yunli; Cridland, Andrew P; Ward, Stuart I; Hackos, David H; Reese, Rebecca M; Shields, Shannon D; Chen, Jun; Balestrini, Alessia; Riol-Blanco, Lorena; Lee, Wyne P; Liu, John; Suto, Eric; Wu, Xiumin; Zhang, Juan; Ly, Justin Q; La, Hank; Johnson, Kevin; Baumgardner, Matt; Chou, Kang-Jye; Rohou, Alexis; Rougé, Lionel; Safina, Brian S; Magnuson, Steven; Volgraf, Matthew.
Afiliação
  • Terrett JA; Department of Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
  • Chen H; Department of Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
  • Shore DG; Department of Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
  • Villemure E; Department of Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
  • Larouche-Gauthier R; Paraza Pharma, Inc. 2525 Avenue Marie-Curie, Montreal, Quebec H4S 2E1, Canada.
  • Déry M; Paraza Pharma, Inc. 2525 Avenue Marie-Curie, Montreal, Quebec H4S 2E1, Canada.
  • Beaumier F; Paraza Pharma, Inc. 2525 Avenue Marie-Curie, Montreal, Quebec H4S 2E1, Canada.
  • Constantineau-Forget L; Paraza Pharma, Inc. 2525 Avenue Marie-Curie, Montreal, Quebec H4S 2E1, Canada.
  • Grand-Maître C; Paraza Pharma, Inc. 2525 Avenue Marie-Curie, Montreal, Quebec H4S 2E1, Canada.
  • Lépissier L; Paraza Pharma, Inc. 2525 Avenue Marie-Curie, Montreal, Quebec H4S 2E1, Canada.
  • Ciblat S; Paraza Pharma, Inc. 2525 Avenue Marie-Curie, Montreal, Quebec H4S 2E1, Canada.
  • Sturino C; Paraza Pharma, Inc. 2525 Avenue Marie-Curie, Montreal, Quebec H4S 2E1, Canada.
  • Chen Y; Pharmaron-Beijing Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, PR China.
  • Hu B; Pharmaron-Beijing Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, PR China.
  • Lu A; Pharmaron-Beijing Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, PR China.
  • Wang Y; Pharmaron-Beijing Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, PR China.
  • Cridland AP; Charles River Laboratories, 8/9 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom.
  • Ward SI; Charles River Laboratories, 8/9 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom.
  • Hackos DH; Department of Neurosciences, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
  • Reese RM; Department of Neurosciences, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
  • Shields SD; Department of Neurosciences, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
  • Chen J; Department of Biochemical and Cellular Pharmacology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
  • Balestrini A; Department of Discovery Immunology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
  • Riol-Blanco L; Department of Discovery Immunology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
  • Lee WP; Department of Translational Immunology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
  • Liu J; Department of Translational Immunology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
  • Suto E; Department of Translational Immunology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
  • Wu X; Department of Translational Immunology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
  • Zhang J; Department of Translational Immunology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
  • Ly JQ; Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
  • La H; Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
  • Johnson K; Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
  • Baumgardner M; Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
  • Chou KJ; Department of Small Molecule Pharmaceutical Sciences, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
  • Rohou A; Department of Structural Biology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
  • Rougé L; Department of Structural Biology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
  • Safina BS; Department of Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
  • Magnuson S; Department of Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
  • Volgraf M; Department of Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
J Med Chem ; 64(7): 3843-3869, 2021 04 08.
Article em En | MEDLINE | ID: mdl-33749283
ABSTRACT
Transient receptor potential ankyrin 1 (TRPA1) is a nonselective calcium-permeable ion channel highly expressed in the primary sensory neurons functioning as a polymodal sensor for exogenous and endogenous stimuli and has generated widespread interest as a target for inhibition due to its implication in neuropathic pain and respiratory disease. Herein, we describe the optimization of a series of potent, selective, and orally bioavailable TRPA1 small molecule antagonists, leading to the discovery of a novel tetrahydrofuran-based linker. Given the balance of physicochemical properties and strong in vivo target engagement in a rat AITC-induced pain assay, compound 20 was progressed into a guinea pig ovalbumin asthma model where it exhibited significant dose-dependent reduction of inflammatory response. Furthermore, the structure of the TRPA1 channel bound to compound 21 was determined via cryogenic electron microscopy to a resolution of 3 Å, revealing the binding site and mechanism of action for this class of antagonists.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Purinas / Asma / Canal de Cátion TRPA1 / Furanos Tipo de estudo: Etiology_studies Limite: Animals / Humans / Male Idioma: En Revista: J Med Chem Assunto da revista: QUIMICA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Purinas / Asma / Canal de Cátion TRPA1 / Furanos Tipo de estudo: Etiology_studies Limite: Animals / Humans / Male Idioma: En Revista: J Med Chem Assunto da revista: QUIMICA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos